Dravet Syndrome

LOS ANGELES — Treatment with cannabidiol led to improved seizure and nonseizure outcomes in patients with various forms of epilepsy, data show.

LOS ANGELES — A wearable, behind-the-ear EEG device is feasible for assessment of sleep patterns in young people with Dravet syndrome, according to a poster presented at the American Epilepsy Society annual meeting.

LOS ANGELES — Zorevunersen led to 75% to 80% seizure reduction in patients with Dravet syndrome, according to Barry S. Ticho, MD, PhD, FACC, chief medical officer of Stoke Therapeutics.

Seizure frequency was reduced as much as 85% at 3 months in young patients with Dravet syndrome treated with a proprietary antisense oligonucleotide, according to results of phase 1/2a studies released by the manufacturer.

Caregivers for those with Lennox Gastaut and Dravet syndrome reported that cannabidiol treatment led to improved nonseizure outcomes and reduced seizure burden, according to a study from Epilepsy Research.

ORLANDO — Although effective treatments have been established for those with epilepsy, there is a need for more and novel therapies, which face barriers of efficacy and access, according to a presenter.

Stoke Therapeutics Inc. has announced new positive data regarding its proprietary antisense oligonucleotide therapeutic to treat Dravet syndrome.

A biotechnology company has announced positive safety and efficacy data from two ongoing phase 1/2a studies as well as an open-label extension study of STK-001 to treat younger individuals with Dravet syndrome.

Stoke Therapeutics Inc. announced the FDA will allow administration of a higher single dose of its investigational drug STK-001 in its ongoing phase 1/2a MONARCH study of children and adolescents with Dravet syndrome.

Clinical outcome assessments currently used for people with Lennox-Gastaut syndrome and Dravet syndrome were “not fit” for evaluating non-seizure outcomes, researchers said, prompting the development of a global clinical impression measure.